{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:24:55Z","timestamp":1648783495464},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T00:00:00Z","timestamp":1398384000000},"content-version":"vor","delay-in-days":4497,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2002]]},"DOI":"10.1016\/s0212-6567(02)79069-0","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T15:15:17Z","timestamp":1365174917000},"page":"442-448","source":"Crossref","is-referenced-by-count":3,"title":["Evaluaci\u00f3n econ\u00f3mica de un nuevo AINE COX-2 selectivo, rofecoxib, en un entorno de pr\u00e1ctica real"],"prefix":"10.1016","volume":"30","author":[{"given":"J.L.","family":"Seg\u00fa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0212-6567(02)79069-0_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.1780380103","article-title":"Nonsteroidal antinflataroy drugs and the gastrointestinal tract: the double edged sword","volume":"38","author":"Lichestein","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/S0212-6567(02)79069-0_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03009749209101382","article-title":"Epidemiology and economics of NSAIDs indiced gastropathy","volume":"21","author":"Zeidler","year":"1992","journal-title":"Scand J Rheumatolo"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0015","unstructured":"Servei Catal\u00e0 de la Salut Departament de Sanitat i Seguretat Social. Pla de Salut 1999\u20132001 de la Regi\u00f3 Sanit\u00e0ria de Barcelona-Ciutat. Barcelona: Servei Catal\u00e0 de la Salut."},{"key":"10.1016\/S0212-6567(02)79069-0_bib0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-199753010-00002","article-title":"NSAID induced gastrointestinal damage: epidemiology, risk and prevention with and evaluation of the role of misoprostol. an Asian-Pacific perspective and consensus","volume":"53","author":"Champion","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0025","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of non-steroidal antinflamatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflamatori drugs. A meta-analysis","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/S0212-6567(02)79069-0_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00019053-200119001-00003","article-title":"A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or Celecoxib in the treatment of arthritis","volume":"19","author":"Burke","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/S0212-6567(02)79069-0_bib0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00019053-200119001-00005","article-title":"Economic evaluation of celecoxib a new cyclo-oxigenase 2 specific inhibitor, in Switzerland","volume":"19","author":"Cjancellor","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/S0212-6567(02)79069-0_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200119001-00004","article-title":"An economic model for determining the costs and consequences of using various treatment alternatives for de management of arthritis in Canada","volume":"19","author":"Zabinski","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0055","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0060","series-title":"Prevention of chronic NSAID induced gastrointestinal toxicity. Cochrane Review. In: The Cochrane Library, Issue 3","author":"Rostom","year":"2000"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/BF02064210","article-title":"Misoprostol coadmisnistred with diclofenac for prevention of gastroduodenal ulcers. A one-year-study","volume":"40","author":"Agrawal","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0149-2918(00)88318-6","article-title":"Comparison of the upper gastrointestinal safety of arthrotec 75 and nabumetone in osteo-arthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers","volume":"21","author":"Agrawal","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0075","first-page":"1602","article-title":"Diclofenac\/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or de hip: A randomiced placebo controlled trial. Arthrotec Osteoarthritis Study Group","volume":"25","author":"Bocanegra","year":"1998","journal-title":"J Rheumatolog"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2036.1998.00288.x","article-title":"Primary gastroduodenal prophylaxis with ompeprazol for non-steroidal antinflammatory drug users","volume":"12","author":"Cullen","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/00365529609010347","article-title":"Prevention of peptic ulcer and dyspeptic syntoms with ompeprazol in patients reciving continuous non-steroidal anti-inflammatory drug therapy. A nordic multicenter study","volume":"31","author":"Ekstr\u00f6m","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazol compared with misoprostol for ulcers associated with non-steroidal antinflammatory drugs. Ompeprazole versus misoprostol for NSAIDs-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM198901123200201","article-title":"Effect of omeprazol and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcers","volume":"320","author":"Walan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omperazole with ranitidine for ulcer associated with nonsteroideal antinflammtory drugs","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0105","first-page":"A171","article-title":"Low frequency of gastrintestinal complications in high risk patients reciving NSAIDs and omperazole","volume":"110","author":"Lanas","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0110","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/gast.1997.v112.pm9178671","article-title":"Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulcerations","volume":"112","author":"Hudson","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"A randomized double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0120","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","article-title":"Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal antinflammatory drugs","volume":"334","author":"Taha","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0125","series-title":"Temas controvertidos en la evaluaci\u00f3n econ\u00f3mica de tecnolog\u00edas sanitarias","author":"Rovira","year":"1995"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0130","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"206","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/S0212-6567(02)79069-0_bib0135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal antinflamatory drugs for osteoarthritis and rheumatoid arthrirtis. The CLASS Study A randomized Controlled Trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656702790690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656702790690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:58:48Z","timestamp":1539737928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656702790690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002]]}},"alternative-id":["S0212656702790690"],"URL":"https:\/\/doi.org\/10.1016\/s0212-6567(02)79069-0","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2002]]}}}